The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results tomorrow afternoon. Here’s what to look for. Vertex Pharmaceuticals beat analysts’ revenue expectations by 3.2% ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Barclays analyst Gena Wang maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $467.00.

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $407 from $402 and keeps a Sector Perform rating on the shares.

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Vertex Securities Ltd share price was down by -3.65% from the previous closing price of ₹4.93. Who are peers of Vertex Securities Ltd? The peers of Vertex Securities Ltd are Motilal Oswal ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...